SOURCE: Plandai Biotechnology, Inc.
SEATTLE, WA--(Marketwired - Jul 17, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced it has executed a contract with KGK Synergize, Inc., a Canadian clinical research and development company, to commence a study measuring human bioavailability -- the percentage of an administered drug that reaches systemic circulation -- of the company's Phytofare™ Catechin Complex.
While earlier bioavailability studies used animal models or involved other Phytofare™ extracts, the KGK study will be the first that tests the absorption properties of the green-tea based Catechin Complex in human subjects. Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "We have vigorously tested our products in numerous laboratory studies and are confident of its properties, but adding scientific validation of Phytofare's™ bioavailability will assist us in making different marketing claims as we prepare for commercial sales at the end of the year."
The bioavailability study will not only test the absorption of Phytofare™ Catechin Complex, but it will compare Phytofare™ against a generic green tea extract and a branded product that touts higher bioavailability.
In addition, Plandaí has contracted with KGK to simultaneously perform a human weight loss trial to test the effects of Phytofare™ Catechin Complex in inducing weight loss while also improving cholesterol and lowering blood pressure. Green tea catechins, specifically the dominant EGCG catechin, have been linked in various other studies to weight loss. Phytofare™ Catechin Extract is a highly bioavailable, molecularly modified green tea-based product engineered for maximum metabolic efficiency. Plandaí believes that Phytofare™ should be able to demonstrate significant health benefits, including weight loss, owing to its higher absorption levels. The human clinical trial will involve 90 subjects, including a placebo group, over three months and will include full blood panels in addition to measuring overall weight loss and changes in fat percentages and mood.
Mr. Duffield added, "Multiple studies have shown that EGCG, a component of green tea, can induce weight loss through thermogenesis. Our research suggests that the synergistic effect of using all of the green tea polyphenols in a highly bioavailable form will lead not only to weight loss but, more importantly, improved health. We intend to use the results from this study to guide us as we explore new drug applications for this remarkable product."
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.